EUVIMEDEUVIMED entdecken
Crossref

Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network

Yohann Pilon, Merav Rokah, Joseph Seitlinger, Boris Sepesi, Roni F Rayes, Jonathan Cools-Lartigue, Sara Najmeh, Christian Sirois, David Mulder, Lorenzo Ferri, Bassam Abdulkarim, Nicole Ezer und 13 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2023.12.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Yohann Pilon und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents are underway. However, significant concerns exist around the feasibility and safety of offering curative surgery to patients treated within such pathways. The goal in this study was to evaluate the impact of a transition towards a large-scale neoadjuvant therapy program for NSCLC. METHODS: Medical charts of patients with clinical stage II and III NSCLC who underwent resection from January 2015 to December 2020 were reviewed. The primary outcome was perioperative complication rate between neoadjuvant-treated versus upfront surgery patients. Multivariable logistic regression estimated occurrence of postoperative complications and overall survival was assessed as an exploratory secondary outcome by Kaplan-Meier and Cox-regression analyses. RESULTS: Of the 428 patients included, 106 (24.8%) received neoadjuvant therapy and 322 (75.2%) upfront surgery. Frequency of minor and major postoperative complications was similar between groups (P = .22). Occurrence in postoperative complication was similar in both cohort (aOR = 1.31, 95% CI 0.73-2.34). Neoadjuvant therapy administration increased from 10% to 45% with a rise in targeted and immuno-therapies over time, accompanied by a reduced rate of preoperative radiation therapy use. 1-, 2-, and 5-year overall survival was higher in neoadjuvant therapy compared to upfront surgery patients (Log-Rank P = .017). CONCLUSIONS: No significant differences in perioperative outcomes and survival were observed in resectable NSCLC patients treated by neoadjuvant therapy versus upfront surgery. Transition to neoadjuvant therapy among resectable NSCLC patients is safe and feasible from a surgical perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsHumansMaleFemaleAgedMiddle AgedPneumonectomyRetrospective StudiesSurvival RatePostoperative ComplicationsTreatment OutcomeNeoplasm StagingFollow-Up Studies

Stichwörter der Autor:innen

Locally advanced non-small cell lung cancerPerioperative outcomesPersonalized medicinePreoperative therapiesThoracic oncology

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • No current official affiliation.
  • Division of Thoracic Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
  • Department of Oncology, McGill University, Montreal, QC, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, QC, Canada.
  • Department of Pathology, McGill University, Montreal, QC, Canada.

Zitieren

APA

Pilon, Y., Rokah, M., Seitlinger, J., Sepesi, B., Rayes, R. F., Cools-Lartigue, J., Najmeh, S., Sirois, C., Mulder, D., Ferri, L., Abdulkarim, B., Ezer, N., Fraser, R., Camilleri-Broët, S., Fiset, P. O., Wong, A., Sud, S., Langleben, A., Agulnik, J., …, & Spicer, J. D. (2024). Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.12.005

Vancouver

Pilon Y, Rokah M, Seitlinger J, Sepesi B, Rayes RF, Cools-Lartigue J, et al. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2023.12.005

BibTeX
@article{Pilon2024,
  author = {Pilon, Yohann and Rokah, Merav and Seitlinger, Joseph and Sepesi, Boris and Rayes, Roni F and Cools-Lartigue, Jonathan and Najmeh, Sara and Sirois, Christian and Mulder, David and Ferri, Lorenzo and Abdulkarim, Bassam and Ezer, Nicole and Fraser, Richard and Camilleri-Broët, Sophie and Fiset, Pierre-Olivier and Wong, Annick and Sud, Shelly and Langleben, Adrian and Agulnik, Jason and Pepe, Carmela and Shieh, Benjamin and Hirsh, Vera and Ofiara, Linda and Owen, Scott and Spicer, Jonathan D},
  title = {Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2023.12.005}
}
Kostenlos starten →